We serve Chemical Name:2-Cyano-N-[2-(trifluoromethyl)phenyl]acetamide CAS:419534-37-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![2-Cyano-N-[2-(trifluoromethyl)phenyl]acetamide](https://a.dearchem.com/CAS2/419534-37-5.png)
Chemical Name:2-Cyano-N-[2-(trifluoromethyl)phenyl]acetamide
CAS.NO:419534-37-5
Synonyms:2-Cyano-N-[2-(trifluoromethyl)phenyl]acetamide
Molecular Formula:C10H7F3N2O
Molecular Weight:228.17100
HS Code:2926909090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:52.89000
Exact Mass:228.05100
LogP:2.63058
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-Cyano-N-[2-(trifluoromethyl)phenyl]acetamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Cyano-N-[2-(trifluoromethyl)phenyl]acetamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Cyano-N-[2-(trifluoromethyl)phenyl]acetamide Use and application,2-Cyano-N-[2-(trifluoromethyl)phenyl]acetamide technical grade,usp/ep/jp grade.
Related News: The researchers found that compared with those with cancer, the prevalence of FT was higher among those with ASCVD (54 versus 41 percent). In adjusted analyses, when studying individual components of FT, those with ASCVD had increased odds of any difficulty paying medical bills, inability to pay bills, cost-related medication nonadherence, food insecurity, and foregone/delayed care due to cost (odds ratios, 1.22, 1.25, 1.28, 1.39, and 1.17, respectively). 2-Cyano-N-[2-(trifluoromethyl)phenyl]acetamide manufacturer I believe they came to the right decision on behalf of the American public, Sandrock said in an interview. 2-Cyano-N-[2-(trifluoromethyl)phenyl]acetamide supplier Advanced clinical trials with the Company��s lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS. 2-Cyano-N-[2-(trifluoromethyl)phenyl]acetamide vendor Advanced clinical trials with the Company��s lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS. 2-Cyano-N-[2-(trifluoromethyl)phenyl]acetamide factory Large pharmaceutical companies are investing a disproportionately large amount of annual revenue in research and development (R&D), according to GlobalData��s Company Financials database.
